Atossa Therapeutics (NASDAQ: ATOS) deepens Z-endoxifen bet as 2025 losses widen and rare disease optionality grows
Read More 2 minute read General news updates Israeli officials debate timing and scale of retaliation against Iran The Israeli war cabinet failed to reach a consensus on how to respond to Iran’s unprecedented attack over… byPallavi MadhirajuApril 15, 2024